Inify Laboratories (INIFY) Q2 2026 earnings summary

Executive summary

• Achieved key milestones with the launch of laboratory and services in the UK, including regulatory approval and first NHS contract.

• Expanded customer base in Sweden with new regional agreements and increased sales.

• Focused on digital, AI-assisted cancer diagnostics, primarily in prostate and gastrointestinal pathology.

Financial highlights

• Net sales for Q2 2026 were SEK 6.3 million, up 14% year-over-year; H1 2026 net sales reached SEK 12.3 million.

• EBITDA for Q2 2026 was SEK -18.1 million, compared to SEK -16.6 million in Q2 2025.

• Net result for Q2 2026 was SEK -21.8 million, compared to SEK -17.2 million in Q2 2025.

• Cash at period end was SEK 90.7 million, down from SEK 129.7 million a year earlier.

• Equity ratio remained strong at 90.0% at the end of Q2 2026.

Outlook and guidance

• Anticipates slightly lower sales growth in Sweden for Q3 2026 due to the holiday period.

• Expects continued growth in both the UK and Sweden, with optimism for additional contracts.